Skip to Content
Jump to the top of the page

Investment Banking

Making Sure America Gets Bang for Its Infrastructure Buck

The country’s electrical, water, telecom, and transit systems are facing years of catch-up repair and maintenance needs—and not even a massive infusion of federal dollars can address all of them. Fortunately, a swarm of companies are specializing in cutting-edge methods of gathering and analyzing data to help assess the areas of greatest need, prioritize initiatives, and maximize government funding.

Those methods fall under the category of Infrastructure Asset Intelligence (IAI). Investors are demonstrating growing interest to partner with companies in the space as they leverage technology to provide accurate, accessible information on the location, specifications, status, and condition of existing infrastructure.

Key takeaways:

  • Why the trillions going toward infrastructure revitalization likely aren't enough
  • The need for better information and analysis on existing infrastructure
  • An overview of the IAI landscape, including segments that will be in high demand in the years ahead

This is the second entry in William Blair’s series, “Investing in Infrastructure Services.” If you’d like to learn more and access detailed research on market participants, accelerating investment activity in the space, and important considerations for potential investors, please contact our team or complete the form below.

Contact Us

Eric Bukovac

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

More News and Insights

  • Abry Partners and CAPZA Have Agreed to Make a Strategic Minority Investment in European Dynamics

    William Blair acted as the exclusive financial advisor to Abry Partners in connection with its pending significant minority investment in European Dynamics, alongside CAPZA.

    Read more
  • William Blair Adds Secondaries Lead in Europe

    William Blair announced today the continued growth of the firm’s Private Capital Advisory team in Europe with the addition of Tim-Oliver Seidel.

    Read more
  • The Quarterly Rx: Q1 2025 U.S. Biopharma Recap

    On Groundhog Day 2025, Punxsutawney Phil saw his shadow and, as per tradition, predicted six more weeks of winter. That proved apropos of biopharma’s performance in the first quarter of 2025, as the sector finds itself reliving existential anxieties.

    Read more

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures